Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 2454 participants.
Also called NCT01481116
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,454 participants
- Sponsor
- Registry
-
NCT01481116 -
2011-001731-24 -
U1111-1124-2296
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Bulgaria, Canada, Colombia, Czechia, Estonia, Hong Kong SAR China, Israel, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Philippines, Poland, Romania, Russia, South Africa, Taiwan, Ukraine, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT01481116. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-03 (actual). Results posted on 2016-06-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- TAK-875
- Intervention (Drug)
- TAK-875
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01481116- Content hash
7d364e0d91a52a095df799fa3b7f57fe0f61e553e40185999b1c897ec317e6b3